Platform Clinical Study for Conquering Scleroderma

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Interstitial Lung Disease Due to Systemic DiseaseScleroderma
Interventions
DRUG

Amlitelimab

"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"

DRUG

BI 1015550 (Nerandomilast)

Study participants will take the active investigational product BI 1015550 (Nerandomilast) or matching placebo provided as film-coated tablets, administered orally BID.

DRUG

Placebo

see Experimental Arm intervention description

Trial Locations (34)

10021

RECRUITING

Hospital for Special Surgery, New York

10032

RECRUITING

Columbia University Medical Center, New York

11021

RECRUITING

Northwell Health, Great Neck

15219

NOT_YET_RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

19104

RECRUITING

University of Pennsylvania, Philadelphia

19107

NOT_YET_RECRUITING

Thomas Jefferson University Hospital, Philadelphia

19140

WITHDRAWN

Temple University Hospital, Philadelphia

20007

RECRUITING

Georgetown University Medical Center - Department of Rheumatology, Washington D.C.

21224

RECRUITING

Johns Hopkins University School of Medicine, Baltimore

27710

NOT_YET_RECRUITING

Duke University Medical Center, Durham

29404

RECRUITING

Medical University of South Carolina (MUSC), Charleston

30322

RECRUITING

Emory University School of Medicine, Atlanta

35294

RECRUITING

University of Alabama - Division of Pulmonary and Critical Care Medicine, Birmingham

37208

WITHDRAWN

Meharry Medical College, Nashville

NOT_YET_RECRUITING

Vanderbilt University Medical Center, Nashville

44195

WITHDRAWN

Cleveland Clinic, Cleveland

53226

RECRUITING

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern University, Chicago

60637

RECRUITING

The University of Chicago Medical Center (UCMC), Chicago

63110

WITHDRAWN

Washington University School of Medicine, St Louis

66160

RECRUITING

University of Kansas School of Medicine, Kansas City

77030

RECRUITING

University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston

84112

WITHDRAWN

The University of Utah Health Sciences Center, Salt Lake City

90033

RECRUITING

Keck School of Medicine at USC Medical Center, Los Angeles

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

94305

RECRUITING

Stanford University Medical Center, Palo Alto

97239

RECRUITING

Oregon Health & Science University (OHSU), Portland

90095-7436

NOT_YET_RECRUITING

University of California, Los Angeles (UCLA) Ronald Reagan Medical Center, Los Angeles

06520

WITHDRAWN

Yale University School of Medicine - Epilepsy, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Boston University (BU), Boston

48109-0370

RECRUITING

University of Michigan, Ann Arbor

08901

RECRUITING

Robert Wood Johnson Medical School, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Scleroderma Research Foundation, Inc.

OTHER

NCT06195072 - Platform Clinical Study for Conquering Scleroderma | Biotech Hunter | Biotech Hunter